Peptide reference

Dosage & Safety Guide

Reference dosing protocols, storage requirements, and safety considerations for research peptides sold by PureLife Health. All products are sold strictly for research purposes only.

Research Use Only

The information on this page is intended for licensed researchers only. PureLife Health products are not approved for human use by Health Canada or the FDA. Consult a qualified medical professional before handling any peptide compounds. This guide does not constitute medical advice.

Storage Protocols

Lyophilized (Powder) Form
  • Store at −20°C (−4°F) long-term or 2–8°C for short-term use
  • Keep away from direct light and moisture
  • Stable for up to 24 months when stored correctly
  • Do not freeze-thaw repeatedly — aliquot before freezing
Reconstituted (Solution) Form
  • Store at 2–8°C (refrigerator) after reconstitution
  • Use within 28–30 days of reconstitution
  • Reconstitute with bacteriostatic water only
  • Label vials with date of reconstitution

Safety Protocols

Handling & PPE

  • Always wear nitrile gloves when handling peptide compounds
  • Use a clean sterile environment (laminar flow hood if possible)
  • Avoid inhaling lyophilized powder — use a mask if needed
  • Dispose of sharps in approved biohazard containers

Reconstitution Safety

  • Use only sterile bacteriostatic water or sterile water for injection
  • Clean vial septa with 70% isopropyl alcohol before each use
  • Insert needle at an angle and allow water to run down the side of the vial
  • Gently swirl — never shake — to avoid denaturing the peptide

Contamination & Disposal

  • Never use a vial that appears cloudy, discoloured, or has visible particles
  • Dispose of expired peptides per local chemical waste regulations
  • Store all compounds out of reach of children and unauthorized personnel
  • Do not use products past their stated expiry date

Peptide Dosage Reference

NAMPT inhibitor that boosts NAD+ levels and enhances energy metabolism.

50-150 mg/day
Oral or subcutaneous injection
Once daily
4-8 weeks
Research compound. Often stacked with NAD+ protocols. Avoid in certain hormone-sensitive conditions.

Copper-binding peptide promoting hair follicle growth, collagen synthesis, and skin repair.

1-2 mg/day injectable; apply topically as directed
Subcutaneous injection or topical
Once daily
4-8 weeks
Reconstitute per vial concentration with bacteriostatic water. Often used in hair and skin research. Well tolerated.

hGH fragment (177-191) targeting fat metabolism without blood sugar effects.

250-500 mcg/day
Subcutaneous injection
Once daily
12 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water. Best administered on an empty stomach in the morning. Well tolerated.

Promotes angiogenesis and upregulates growth hormone receptors to accelerate tissue repair.

250-500 mcg/day
Subcutaneous or intramuscular injection
Once or twice daily
4-6 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water (2.5mg/mL). Often administered near the site of injury. No major side effects reported in studies. Avoid if pregnant or immunocompromised.

BPC-157

Promotes angiogenesis and upregulates growth hormone receptors to accelerate tissue repair.

250-500 mcg/day
Subcutaneous or intramuscular injection
Once or twice daily
4-6 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water (2.5mg/mL). Often administered near the site of injury. No major side effects reported in studies. Avoid if pregnant or immunocompromised.

GHK-Cu (Copper Peptide)

Copper-binding peptide that promotes collagen synthesis, wound healing, and antioxidant defense.

1-2 mg/day injectable; apply topically as directed
Subcutaneous injection or topical
Once daily
4-8 weeks
Reconstitute a 50mg vial with 5mL bacteriostatic water (10mg/mL). Very well tolerated; topical may cause mild redness. Avoid with active copper metabolism disorders.

KPV

Anti-inflammatory peptide derived from alpha-MSH; gut-healing and immune modulation.

100-500 mcg/day (or 1-5mg/week)
Subcutaneous injection or oral
Once daily
4-8 weeks
Reconstitute a 10mg vial with 2mL bacteriostatic water. Potent anti-inflammatory. Well tolerated in research.

TB-500 (Thymosin Beta-4)

Regulates actin polymerization, promoting cell migration and differentiation for wound healing.

2-2.5 mg twice per week (loading); 1.25-2.5 mg/week (maintenance)
Subcutaneous injection
Twice weekly loading, weekly maintenance
4-6 weeks loading, ongoing maintenance
Reconstitute a 10mg vial with 2mL bacteriostatic water (5mg/mL). Generally well-tolerated; may cause mild fatigue or head rush post-injection. Not recommended for individuals with a history of cancer.

BPC-157

Promotes angiogenesis and upregulates growth hormone receptors to accelerate tissue repair.

250-500 mcg/day
Subcutaneous or intramuscular injection
Once or twice daily
4-6 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water (2.5mg/mL). Often administered near the site of injury. No major side effects reported in studies. Avoid if pregnant or immunocompromised.

GHK-Cu (Copper Peptide)

Copper-binding peptide that promotes collagen synthesis, wound healing, and antioxidant defense.

1-2 mg/day injectable; apply topically as directed
Subcutaneous injection or topical
Once daily
4-8 weeks
Reconstitute a 50mg vial with 5mL bacteriostatic water (10mg/mL). Very well tolerated; topical may cause mild redness. Avoid with active copper metabolism disorders.

TB-500 (Thymosin Beta-4)

Regulates actin polymerization, promoting cell migration and differentiation for wound healing.

2-2.5 mg twice per week (loading); 1.25-2.5 mg/week (maintenance)
Subcutaneous injection
Twice weekly loading, weekly maintenance
4-6 weeks loading, ongoing maintenance
Reconstitute a 10mg vial with 2mL bacteriostatic water (5mg/mL). Generally well-tolerated; may cause mild fatigue or head rush post-injection. Not recommended for individuals with a history of cancer.

BPC-157

Promotes angiogenesis and upregulates growth hormone receptors to accelerate tissue repair.

250-500 mcg/day
Subcutaneous or intramuscular injection
Once or twice daily
4-6 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water (2.5mg/mL). Often administered near the site of injury. No major side effects reported in studies. Avoid if pregnant or immunocompromised.

KPV

Anti-inflammatory peptide derived from alpha-MSH; gut-healing and immune modulation.

100-500 mcg/day (or 1-5mg/week)
Subcutaneous injection or oral
Once daily
4-8 weeks
Reconstitute a 10mg vial with 2mL bacteriostatic water. Potent anti-inflammatory. Well tolerated in research.

TB-500 (Thymosin Beta-4)

Regulates actin polymerization, promoting cell migration and differentiation for wound healing.

2-2.5 mg twice per week (loading); 1.25-2.5 mg/week (maintenance)
Subcutaneous injection
Twice weekly loading, weekly maintenance
4-6 weeks loading, ongoing maintenance
Reconstitute a 10mg vial with 2mL bacteriostatic water (5mg/mL). Generally well-tolerated; may cause mild fatigue or head rush post-injection. Not recommended for individuals with a history of cancer.

BPC-157

Promotes angiogenesis and upregulates growth hormone receptors to accelerate tissue repair.

250-500 mcg/day
Subcutaneous or intramuscular injection
Once or twice daily
4-6 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water (2.5mg/mL). Often administered near the site of injury. No major side effects reported in studies. Avoid if pregnant or immunocompromised.

TB-500 (Thymosin Beta-4)

Regulates actin polymerization, promoting cell migration and differentiation for wound healing.

2-2.5 mg twice per week (loading); 1.25-2.5 mg/week (maintenance)
Subcutaneous injection
Twice weekly loading, weekly maintenance
4-6 weeks loading, ongoing maintenance
Reconstitute a 10mg vial with 2mL bacteriostatic water (5mg/mL). Generally well-tolerated; may cause mild fatigue or head rush post-injection. Not recommended for individuals with a history of cancer.

Amylin and calcitonin receptor agonist promoting appetite suppression.

Titrate 0.6mg → 1.2mg → 2.4mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration. Titrate gradually to minimize GI effects. Often combined with GLP-1 agonists in research protocols.

Cagrilintide

Amylin and calcitonin receptor agonist promoting appetite suppression.

Titrate 0.6mg → 1.2mg → 2.4mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration. Titrate gradually to minimize GI effects. Often combined with GLP-1 agonists in research protocols.

Retatrutide

Triple GLP-1, GIP, and glucagon receptor agonist for weight loss and metabolic regulation.

Titrate 1mg → 2mg → 4mg → 6mg → 8mg → 12mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration with bacteriostatic water. Titrate every 2-4 weeks per tolerance. GI effects (nausea, diarrhea) common. Research compound — not FDA approved.

Cagrilintide

Amylin and calcitonin receptor agonist promoting appetite suppression.

Titrate 0.6mg → 1.2mg → 2.4mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration. Titrate gradually to minimize GI effects. Often combined with GLP-1 agonists in research protocols.

Semaglutide

GLP-1 receptor agonist for appetite suppression and weight loss.

Titrate 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration. Titrate every 4 weeks. Nausea common, especially at initiation.

Cagrilintide

Amylin and calcitonin receptor agonist promoting appetite suppression.

Titrate 0.6mg → 1.2mg → 2.4mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration. Titrate gradually to minimize GI effects. Often combined with GLP-1 agonists in research protocols.

Tirzepatide

Dual GLP-1 and GIP receptor agonist for weight loss and glycemic control.

Titrate 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration with bacteriostatic water. Increase dose every 4 weeks. GI side effects (nausea, vomiting) common. Titrate slowly.

Peptide bioregulator targeting cartilage and joint tissue regeneration.

1-2 mg/day
Subcutaneous injection or oral
Once daily
1 month, repeat as needed
Reconstitute per vial concentration. Well tolerated. Cyclic use recommended.

Combined NAD+ and mitochondrial-support compounds for cellular energy.

Per included kit instructions
Subcutaneous or IV
As directed per compound
4-8 weeks
Follow the dosing card included with the kit. Research use only.

GHRH analogue that extends the half-life of growth hormone-releasing hormone pulses.

1-2 mg/week (no DAC); 2 mg/week (DAC)
Subcutaneous injection
Once or twice weekly
8-12 weeks
DAC form has a longer half-life (weekly dosing); no-DAC dosed 2-3x/week. Often stacked with Ipamorelin for synergistic GH release. May cause water retention, joint discomfort, or tingling initially.

CJC-1295

GHRH analogue that extends the half-life of growth hormone-releasing hormone pulses.

1-2 mg/week (no DAC); 2 mg/week (DAC)
Subcutaneous injection
Once or twice weekly
8-12 weeks
DAC form has a longer half-life (weekly dosing); no-DAC dosed 2-3x/week. Often stacked with Ipamorelin for synergistic GH release. May cause water retention, joint discomfort, or tingling initially.

Ipamorelin

Mimics ghrelin to selectively stimulate GH release from the pituitary without significant side effects.

200-300 mcg per injection
Subcutaneous injection
2-3 times daily
8-12 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water. Highly selective GH secretagogue with minimal cortisol or prolactin stimulation. Best used before bed or post-workout.

Combined nootropic peptides targeting cognitive enhancement and neuroprotection.

Per included kit instructions
Subcutaneous or intranasal
As directed per compound
4-8 weeks
Follow the dosing card included with the kit. Research use only.

Modulates sleep via GABA and serotonin pathways; also exhibits antioxidant properties.

100-500 mcg
Subcutaneous injection or intranasal
Before sleep, as needed
Short-term cycles of 1-2 weeks
Reconstitute per vial concentration. Generally mild; may cause drowsiness. Avoid driving after administration. Best used in short cycles to prevent tolerance.

Tetrapeptide that stimulates telomerase activity, potentially lengthening telomeres and regulating melatonin.

5-10 mg/day
Subcutaneous injection or intranasal
Once daily
10-20 days, 1-2 times per year
Reconstitute a 10mg vial with 1-2mL bacteriostatic water. Considered very safe with no significant side effects in studies. Cycled twice yearly for longevity protocols.

Senolytic peptide that selectively clears senescent cells by disrupting FOXO4-p53 binding.

1-5 mg/week
Subcutaneous injection
Once weekly
4-8 weeks (senolytic cycles)
Reconstitute per vial concentration with bacteriostatic water. Research senolytic. Best used in intermittent cycles.

Copper-binding peptide that promotes collagen synthesis, wound healing, and antioxidant defense.

1-2 mg/day injectable; apply topically as directed
Subcutaneous injection or topical
Once daily
4-8 weeks
Reconstitute a 50mg vial with 5mL bacteriostatic water (10mg/mL). Very well tolerated; topical may cause mild redness. Avoid with active copper metabolism disorders.

Master antioxidant supporting detoxification, immune function, and skin brightening.

600-1500 mg
IV, IM, or subcutaneous injection
1-3 times per week
4-8 weeks
IV push slowly. Well tolerated. Often used in oxidative stress and skin-brightening research.

Luteinizing hormone analogue supporting testosterone production and fertility.

250-500 IU
Intramuscular or subcutaneous injection
2-3 times per week
Per protocol (3-8 weeks)
Reconstitute with bacteriostatic water. Store reconstituted vial refrigerated. Well tolerated in research protocols.

Recombinant growth hormone supporting muscle growth, recovery, and metabolism.

1-4 IU/day
Subcutaneous injection
Once daily
3-6 months
Reconstitute with bacteriostatic water. Requires careful dosing. Water retention, joint pain, and carpal tunnel symptoms possible. Research use only.

Insulin-like growth factor analogue promoting muscle growth, recovery, and nutrient partitioning.

20-50 mcg/day
Subcutaneous or intramuscular injection
Once daily
4-6 weeks
Reconstitute a 1mg vial with 2mL bacteriostatic water (0.5mg/mL). Hypoglycemia risk — monitor blood sugar. Research compound.

Mimics ghrelin to selectively stimulate GH release from the pituitary without significant side effects.

200-300 mcg per injection
Subcutaneous injection
2-3 times daily
8-12 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water. Highly selective GH secretagogue with minimal cortisol or prolactin stimulation. Best used before bed or post-workout.

Ipamorelin

Mimics ghrelin to selectively stimulate GH release from the pituitary without significant side effects.

200-300 mcg per injection
Subcutaneous injection
2-3 times daily
8-12 weeks
Reconstitute a 5mg vial with 2mL bacteriostatic water. Highly selective GH secretagogue with minimal cortisol or prolactin stimulation. Best used before bed or post-workout.

Tesamorelin

GHRH analogue that increases endogenous GH and IGF-1 (FDA approved for lipodystrophy).

2 mg/day
Subcutaneous injection
Once daily
6+ months
Reconstitute per kit instructions. Injection-site reactions common. Best administered in the evening.

Stimulates GnRH release to regulate reproductive hormone signaling.

1-5 mg/week
Subcutaneous injection
Once weekly
4-8 weeks
Reconstitute per vial concentration with bacteriostatic water. Research compound. Well tolerated in studies.

Anti-inflammatory peptide derived from alpha-MSH; gut-healing and immune modulation.

100-500 mcg/day (or 1-5mg/week)
Subcutaneous injection or oral
Once daily
4-8 weeks
Reconstitute a 10mg vial with 2mL bacteriostatic water. Potent anti-inflammatory. Well tolerated in research.

Transports fatty acids into mitochondria for energy production and fat metabolism.

500-1000 mg
IM, IV, or oral
Once daily to weekly
Ongoing
IM injection may sting. Best administered pre-workout. Well tolerated.

Riboflavin, PPC, and bromelain blend for local fat lipolysis.

Clinic-administered per treatment area
Subcutaneous (local lipolysis)
Per session, 3-4 weeks apart
Multiple sessions
Clinic-administered only. Swelling and tenderness expected post-treatment.

Lipotropic B-vitamin blend supporting fat metabolism and energy.

1 mL per injection
IM or subcutaneous injection
Once weekly
4-8 weeks
IM injection most common. Rotate injection sites. Well tolerated.

Lipotropic blend (methionine, inositol, choline, B12) supporting fat metabolism.

1 mL per injection
IM or subcutaneous injection
Once weekly
4-8 weeks
IM injection most common. Rotate injection sites. Well tolerated.

Combined metabolic and mitochondrial support peptides for longevity research.

Per included kit instructions
Subcutaneous injection
As directed per compound
8-12 weeks
Follow the dosing card included with the kit. Contains research peptides targeting metabolic function.

Mitochondrial-derived peptide that activates AMPK and regulates metabolic function.

5-10 mg/week
Subcutaneous injection
1-2 times per week
4-8 weeks
Reconstitute a 10mg vial with 1mL bacteriostatic water. Exercise mimetic. Well tolerated in research.

Essential coenzyme for cellular energy (ATP) production and sirtuin activation.

50-100mg titrating to 500-1000mg
IV, IM, or subcutaneous injection
Once daily to weekly
4-8 weeks
IV administration may cause flushing, warmth, and muscle cramping. Start low and titrate. Best administered slowly.

Peptide bioregulator targeting brain and cognitive function.

1-2 mg/day
Subcutaneous injection or oral
Once daily
10-20 days
Reconstitute per vial concentration. Well tolerated. Cyclic use recommended.

Melanocortin receptor agonist acting on the CNS to modulate sexual arousal.

1-2 mg
Subcutaneous injection or nasal spray
As needed, at least 45 min before activity
On-demand use
Reconstitute a 10mg vial with 1mL bacteriostatic water. May cause transient nausea, flushing, or elevated blood pressure. Do not exceed 1 dose per 72 hours. Avoid with cardiovascular conditions.

Triple GLP-1, GIP, and glucagon receptor agonist for weight loss and metabolic regulation.

Titrate 1mg → 2mg → 4mg → 6mg → 8mg → 12mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration with bacteriostatic water. Titrate every 2-4 weeks per tolerance. GI effects (nausea, diarrhea) common. Research compound — not FDA approved.

Anxiolytic peptide with immune-modulating effects; non-sedating stress reduction.

250-900 mcg/day
Intranasal or subcutaneous injection
1-2 times daily
2-4 weeks
Intranasal route is most common. Non-sedating. Well tolerated in research.

GLP-1 receptor agonist for appetite suppression and weight loss.

Titrate 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration. Titrate every 4 weeks. Nausea common, especially at initiation.

ACTH-derived nootropic peptide enhancing cognition, memory, and BDNF expression.

300-600 mcg/day
Intranasal or subcutaneous injection
1-2 times daily
2-4 weeks
Intranasal route is most common. Well tolerated. Cyclic use recommended.

Acetyl octapeptide-3 providing botox-like muscle relaxation to reduce expression wrinkles.

Topical application as directed
Topical (cosmetic)
Once or twice daily
Ongoing
Cosmetic topical only — not for injection. Apply to clean skin. Well tolerated.

Mitochondrial-targeted peptide that binds cardiolipin and protects mitochondrial function.

1-5 mg/week
Subcutaneous injection
Once weekly
4-8 weeks
Reconstitute per vial concentration with bacteriostatic water. Research compound. Well tolerated in studies.

Regulates actin polymerization, promoting cell migration and differentiation for wound healing.

2-2.5 mg twice per week (loading); 1.25-2.5 mg/week (maintenance)
Subcutaneous injection
Twice weekly loading, weekly maintenance
4-6 weeks loading, ongoing maintenance
Reconstitute a 10mg vial with 2mL bacteriostatic water (5mg/mL). Generally well-tolerated; may cause mild fatigue or head rush post-injection. Not recommended for individuals with a history of cancer.

GHRH analogue that increases endogenous GH and IGF-1 (FDA approved for lipodystrophy).

2 mg/day
Subcutaneous injection
Once daily
6+ months
Reconstitute per kit instructions. Injection-site reactions common. Best administered in the evening.

Dual GLP-1 and GIP receptor agonist for weight loss and glycemic control.

Titrate 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg once weekly
Subcutaneous injection
Once weekly
12+ weeks
Reconstitute per vial concentration with bacteriostatic water. Increase dose every 4 weeks. GI side effects (nausea, vomiting) common. Titrate slowly.

Dosage ranges are based on current published research and may change as new data becomes available. Always verify against the most recent scientific literature.